Developing the Next Generation of Dermatology Treatments
Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.
Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa.
Resources
FOR HEALTHCARE PROFESSIONALS
Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please visit incyteglobalmedicalinformation.com.
Please call Incyte European Medical Information department on 00-800-0002-7423 or Direct Dial for the UK only +44 1423 533 517 / 03301003677 or email EU Incyte Call Center eumedinfo@incyte.com. For UK general enquiries, please email UK_enquiries@incyte.com.
UK Adverse Event Reporting Information:
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events can also be reported to Incyte by calling 03301003677 (Great Britain) or 00-800-0002-7423 (United Kingdom [Northern Ireland]).
Ireland Adverse Event Reporting Information:
Adverse events should be reported. Reporting forms and information can be found at: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Incyte by calling 00-800-0002-7423.